| |
| |
|
| Insider
Information: |
Schreiber Alain |
| Relationship: |
10% Owner |
| City: |
Princeton |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
12,051,047 |
|
|
Indirect Shares
|
11,491,339 |
|
|
| Direct
Value |
$27,342,535 |
|
|
|
Indirect Value
|
$2,610,128 |
|
|
| Total
Shares |
23,542,386 |
|
|
| Total
Value |
$29,952,663 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Molecular Templates, Inc. |
MTEM |
10% Owner |
2005-10-28 |
136,417 |
2005-10-28 |
3,385,203 |
Premium* |
|
|
Palatin Technologies Inc |
PTN |
10% Owner |
2005-11-29 |
5,803,972 |
2005-11-29 |
0 |
Premium* |
|
|
Cadence Pharmaceuticals Inc |
CADX |
Director, 10% Owner |
2007-09-19 |
2,882,269 |
2006-10-30 |
12,500 |
Premium* |
|
|
Optimer Pharmaceuticals Inc |
OPTR |
Director |
2008-07-18 |
2,500 |
2009-03-04 |
811,998 |
Premium* |
|
|
Avanir Pharmaceuticals |
AVNR |
10% Owner |
2008-08-06 |
0 |
2009-10-13 |
7,125,754 |
Premium* |
|
|
Eagle Pharmaceuticals, Inc. |
EGRX |
10% Owner |
|
0 |
2017-05-15 |
155,884 |
Premium* |
|
|
Immune Design Corp. |
IMDZ |
10% Owner |
2015-05-12 |
1,983,858 |
2015-03-05 |
0 |
Premium* |
|
|
Urogen Pharma Ltd. |
URGN |
10% Owner |
2017-11-28 |
1,242,031 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
117 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MTEM |
Molecular Templates, Inc. |
10% Owner |
– – • |
2005-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,440,205 |
|
- |
|
| AVNR |
Avanir Pharmaceuticals |
10% Owner |
– – • |
2008-08-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,820,470 |
|
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
Director |
– • • |
2014-02-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
48,361 |
|
- |
|
| URGN |
Urogen Pharma Ltd. |
10% Owner |
– – • |
2017-05-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,451,329 |
|
- |
|
| CADX |
Cadence Pharmaceuticals I... |
Director |
– • • |
2006-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,053,174 |
3,053,174 |
0 |
- |
|
| OPTR |
Optimer Pharmaceuticals I... |
Director |
– • – |
2007-02-14 |
4 |
A |
$0.00 |
$0 |
I/I |
1,076,902 |
43,827 |
0 |
- |
|
| OPTR |
Optimer Pharmaceuticals I... |
Director |
– • – |
2007-09-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,500 |
2,500 |
0 |
- |
|
| OPTR |
Optimer Pharmaceuticals I... |
Director |
– • – |
2009-03-04 |
4 |
B |
$0.00 |
$0 |
I/I |
457,666 |
811,998 |
2.02 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
Director |
– • • |
2014-02-18 |
4 |
A |
$0.00 |
$0 |
I/I |
4,448,591 |
71,934 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
Director |
– • • |
2014-02-18 |
4 |
OE |
$0.00 |
$0 |
I/I |
22,194 |
72,291 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
Director |
– • • |
2014-02-18 |
4 |
A |
$0.00 |
$0 |
I/I |
4,448,591 |
71,934 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
Director |
– • • |
2015-05-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,903) |
62,031 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
Director |
– • • |
2015-07-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,970) |
59,061 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
Director |
– • • |
2016-05-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,780,188) |
9,360 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
10% Owner |
– – • |
2016-06-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,903) |
5,582 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
10% Owner |
– – • |
2017-05-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,584,087) |
0 |
0 |
- |
|
| EGRX |
Eagle Pharmaceuticals, In... |
10% Owner |
– – • |
2017-05-15 |
4 |
A |
$0.00 |
$0 |
I/I |
298,214 |
149,107 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
10% Owner |
– – • |
2008-08-06 |
4 |
B |
$0.90 |
$360 |
I/I |
400 |
7,820,870 |
1.42 |
- |
|
| IMDZ |
Immune Design Corp. |
10% Owner |
– – • |
2015-04-16 |
4 |
S |
$26.75 |
$2,675 |
D/D |
(100) |
2,290,177 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
Director |
– • • |
2007-09-17 |
4 |
S |
$13.50 |
$2,700 |
D/D |
(200) |
2,918,969 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
10% Owner |
– – • |
2008-10-15 |
4 |
B |
$0.49 |
$3,168 |
I/I |
6,465 |
9,788,266 |
1.42 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
10% Owner |
– – • |
2008-10-22 |
4 |
B |
$0.48 |
$5,088 |
I/I |
10,600 |
9,798,866 |
1.5 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
10% Owner |
– – • |
2008-08-14 |
4 |
B |
$0.90 |
$5,446 |
I/I |
6,051 |
7,918,301 |
1.5 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
10% Owner |
– – • |
2008-09-03 |
4 |
B |
$0.93 |
$6,384 |
I/I |
6,864 |
8,452,194 |
1.5 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
Director |
– • • |
2007-09-14 |
4 |
S |
$13.50 |
$6,750 |
D/D |
(500) |
2,919,169 |
0 |
- |
|
117 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
